Danaher (DHR) Financial Analysis & Valuation | Quarter Chart
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectr... more
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commer... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $161.01B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Julie Sawyer Montgomery |
| IPO Date | 1978-12-29 | CAGR | 11.66% |
| Employees | 59,000 | Website | www.danaher.com |
| Div. Yield | 0.02% | Payout Ratio | 25% |
| Buy Back Yield | 0.02% | Total Yield | 0.04% |
DHR chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $197.56B | P/E | 28.7 | Forward P/E | 24.64 | PEG | 0.69 |
| P/S | 380345.64 | P/B | 177543.25 | P/CF | 1463084.92 | P/FCF | 1780689.29 |
| Sales | $25.11B | Sales 1Y | 4.56% | Sales 3Y | -10.02% | Sales 5Y | -6.03% |
| EPS | $7.98 | EPS 1Y | 19.79% | EPS 3Y | -33.69% | EPS 5Y | -25.03% |
| Sales QoQ | 5.28% | EPS QoQ | -15.17% | Sales QoQ Avg | 1.81% | EPS QoQ Avg | 17.09% |
| Gross Margin | 60.68% | Operating Margin | 20.95% | Profit Margin | 14.89% | ROCE | 6.82% |
| ROA | 4% | ROE | 7% | Altman Z Score | 3.95 | Piotroski Score | 6 |
| Current Ratio | 1.87 | Quick Ratio | 1.52 | Cash Ratio | 0.76 | Op. CF Ratio | 0.19 |
| Debt/Equity | 0.35 | Debt/Assets | 0.29 | Lt Debt/Equity | 0.48 | Lt Debt/Cap. | 0.25 |
| Intrst Cov. | 20.28 | Inventory Turnover | 3.74 | Asset Turnover | 0.3 | Receivables Turnover | 6.49 |
| Enterprise Value | $197.56B | P/E Ratio | 28.7 |
| Forward P/E | 24.64 | PEG Ratio | 0.69 |
| P/S Ratio | 380345.64 | P/B Ratio | 177543.25 |
| P/CF Ratio | 1463084.92 | P/FCF Ratio | 1780689.29 |
| EPS | $7.98 | EPS Growth 1Y | 19.79% |
| EPS Growth 3Y | -33.69% | EPS Growth 5Y | -25.03% |
| Revenue Growth 1Y | 4.56% | Gross Margin | 60.68% |
| Operating Margin | 20.95% | Profit Margin | 14.89% |
| ROE | 7% | ROA | 4% |
| ROCE | 6.82% | Current Ratio | 1.87 |
| Quick Ratio | 1.52 | Cash Ratio | 0.76 |
| Debt/Equity | 0.35 | Interest Coverage | 20.28 |
| Altman Z Score | 3.95 | Piotroski Score | 6 |
Danaher (DHR) valuation & financials
Danaher (DHR) has a market capitalization of $161.01B and trades at a price-to-earnings ratio of 28.7. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Danaher's revenue grew +4.6% over the last year.
Danaher's next earnings report is scheduled for October 21, 2026 before market open (provider scheduled date); analysts estimate EPS of $1.91. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)